Stockscreener 앱 받기
1,024.58
1.92%
-20.09
시간 외 거래:
1027.00
2.42
+0.24%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly's orforglipron - Seeking Alpha
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal - The Globe and Mail
Lilly’s ENLIGHTEN-4 Trial Targets Knee Osteoarthritis Pain in Overweight Patients - TipRanks
Eli Lilly stock price target maintained at $1,250 by UBS on orforglipron outlook - Investing.com
Innovent-Lilly $8.5B deal signals new China inflection point - BioWorld MedTech
Innovent Deepens Eli Lilly Tie-Up With Potential $8.9 Billion Drug Deal - Caixin Global
Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026 - Yahoo Finance
BMO Capital reiterates Eli Lilly stock rating at Outperform on Orna acquisition - Investing.com
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know. - The Motley Fool
FDA cardiovascular indication for semaglutide led to short-term uptake but persistent treatment gaps among high-risk patients, new Truveta study finds - GlobeNewswire Inc.
Eli Lilly and Company $LLY Shares Bought by Navellier & Associates Inc. - MarketBeat
Eli Lilly to Acquire Orna Therapeutics for $2.4B in Cell Therapy Deal - Eudaimonia and Co
ProShare Advisors LLC Sells 2,202 Shares of Eli Lilly and Company $LLY - MarketBeat
Rockland Trust Co. Increases Position in Eli Lilly and Company $LLY - MarketBeat
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? - The Motley Fool
Innovent, Eli Lilly sign drug deal - KrASIA
UBS Envisions INNOVENT BIO's Partnership with Eli Lilly to Provide Upside for Drug Advancement Targets - AASTOCKS.com
Innovent Bio rises again after reaching its seventh global strategic collaboration with Eli Lilly and Co. Goldman Sachs indicates its stock is undervalued. - 富途牛牛
Innovent, Lilly ink pact for novel drugsChina Daily - China Daily - Global Edition
Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion - Barron's
Eli Lilly to Buy Orna Therapeutics in $2.4B RNA Bet - USA Herald
Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy - Law360
LLY Stock Rises As Lilly Bets $2.4 Billion On Next-Gen RNA Cell Therapies - Stocktwits
Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion - The Wall Street Journal
QuantX Biosciences US Inc. announced that it has received $85 million in funding from Sanofi, Eli Lilly Investment Consulting Co., Ltd. and other investors - marketscreener.com
New peptide drugs on the horizon with PepLib–Lilly collab - longevity.technology
Eli Lilly to acquire 'world's most innovative biotech startup' for up to $2.4B - The Business Journals
Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals - BioPharma Dive
Lilly to acquire Massachusetts-based cell therapy firm for $2.4B - Inside INdiana Business
Lilly buying CAR T firm Orna in $2.4B deal - BioWorld MedTech
Eli Lilly Launches Multi-Billion Dollar Expansion in Key Therapeutic Areas - AD HOC NEWS
Why Eli Lilly Stock Just Popped - The Motley Fool
Eli Lilly Stock (LLY) Rises on News Its Buying Orna Therapeutics for $2.4 Billion - TipRanks
Eli Lilly (LLY) Acquires Orna Therapeutics in $2.4 Billion Deal - GuruFocus
Eli Lilly and Co will acquire Orna Therapeutics, an immunocyte engineering company. - 富途牛牛
U.S. Stock Movement | Eli Lilly and Co (LLY.US) Rises Over 3% on Announcement of Acquisition of Immunocyte Engineering Company Orna Therapeutics - 富途牛牛
Eli Lilly stock maintains Outperform rating at Bernstein amid GLP-1 market disruption concerns - Investing.com India
International business briefs: Eli Lilly to buy Orna Therapeutics for up to $2.4bn - Business Day
Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments - Benzinga
Stock Movers: Hims & Hers, Eli Lilly, Alphabet - Bloomberg
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Lilly deepens Innovent ties with $350 million oncology and immunology pact - The Pharma Letter
Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena - Fierce Biotech
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Lilly Strikes Deal for Biotech Orna Worth Up to $2.4 Billion - Bloomberg
Why Is Eli Lilly (LLY) Stock Up Premarket? $2.4B Biotech Acquisition - Tokenist
Novo Nordisk, Kroger and Eli Lilly rise premarket; Micron falls By Investing.com - Investing.com Australia
UBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,250 - 富途牛牛
Lilly to buy Orna for up to $2.4B, expanding cell therapy pipeline - FirstWord Pharma
Lilly to acquire Orna Therapeutics for up to $2.4 billion By Investing.com - Investing.com India
Lilly to acquire Orna Therapeutics for up to $2.4 billion - Investing.com
Lilly Agrees To Acquire Orna Therapeutics For Up To $2.4 Bln In Cash - Nasdaq
Eli Lilly to buy Orna Therapeutics for up to $2.4B in cash (LLY:NYSE) - Seeking Alpha
Lilly to Acquire Orna Therapeutics - citybiz
Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna - Reuters
Lilly to acquire Orna Therapeutics to advance cell therapies - Eli Lilly
Mounjaro Market to Boom Worldwide By 2026-2033| Eli Lilly and Company - openPR.com
Eli Lilly (LLY) Stock Bets Big on China Biotech With $8.5B Innovent Deal - CoinCentral
Upfront payment of $350 million, with a total value of $8.5 billion! Innovent Bio partners with Eli Lilly and Co to advance R&D in novel cancer immunotherapy drugs. - 富途牛牛
Alteogen says monthly obesity shot matches Lilly's retatrutide weight loss in rats - koreabiomed.com
Innovent Biologics shares surge on $350 mln Eli Lilly partnership By Investing.com - Investing.com Nigeria
Innovent Biologics shares surge on $350 mln Eli Lilly partnership - Investing.com
Lilly Inks Deal with Innovent to Speed Up Early Drug Development - bloomberg.com
China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
0.12%
0.73%
자본화:
|
볼륨(24시간):